Market closedNon-fractional
Repare Therapeutics/RPTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Repare Therapeutics
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Ticker
RPTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Montréal, Canada
Employees
179
Website
www.reparerx.com
RPTX Metrics
BasicAdvanced
$166M
Market cap
-
P/E ratio
-$1.08
EPS
0.70
Beta
-
Dividend rate
Price and volume
Market cap
$166M
Beta
0.7
Financial strength
Current ratio
8.331
Quick ratio
8.217
Long term debt to equity
0.242
Total debt to equity
1.198
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-18.91%
Valuation
Price to revenue (TTM)
1.679
Price to book
0.72
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-1.936
Growth
Revenue change (TTM)
-28.62%
Earnings per share change (TTM)
55.68%
3-year revenue growth (CAGR)
587.61%
3-year earnings per share growth (CAGR)
-20.47%
What the Analysts think about RPTX
Analyst Ratings
Majority rating from 7 analysts.
RPTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$52M
303.08%
Net income
$13M
-146.79%
Profit margin
25.00%
-111.61%
RPTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.28
-$0.45
-$0.67
$0.30
-
Expected
-$0.78
-$0.86
-$0.36
$0.02
-$0.87
Surprise
-64.10%
-47.60%
86.85%
1,809.13%
-
RPTX News
AllArticlesVideos
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Business Wire·4 weeks ago
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Business Wire·1 month ago
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repare Therapeutics stock?
Repare Therapeutics (RPTX) has a market cap of $166M as of July 27, 2024.
What is the P/E ratio for Repare Therapeutics stock?
The price to earnings (P/E) ratio for Repare Therapeutics (RPTX) stock is 0 as of July 27, 2024.
Does Repare Therapeutics stock pay dividends?
No, Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Repare Therapeutics dividend payment date?
Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Repare Therapeutics?
Repare Therapeutics (RPTX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Repare Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.